Mr. Andre Larente reports

DIAGNOS ANNOUNCES PARTNERSHIP IN SAUDI ARABIA WITH MAGRABI HOSPITALS AND CENTERS TO SCREEN DIABETIC PATIENTS

Diagnos Inc. has opened five screening clinics at various locations of Magrabi Hospital & Centers located in Riyadh, with the help of its Saudi business partner, Kanhoor Medical Co.

Magrabi is one of the largest eye-care networks in the world, providing eye care to more than one million patients and performing more than 100,000 sight-preserving surgeries annually. Magrabi operates in 30 locations in the Kingdom of Saudi Arabia, United Arab Emirates, Qatar, Saltanat of Oman, Yemen and Egypt.

Magrabi is launching Diagnos's artificial-intelligence-assisted screening project to increase the availability of this service to its large number of diabetic patients. Being more strategically located near the patient base, CARA can offer its service to dramatically increase its volume of medical tests in a short period of time. Following the prompt execution of this project, the plan is to extend the screening to all Magrabi hospitals in Saudi Arabia, the Middle East and Africa.

"This project is the result of many months of detailed work with Magrabi and two field trials. This commercial project is establishing the foundation of a partnership between Magrabi, Kanhoor and Diagnos to deploy in the remaining 22 clinics in Saudi Arabia in the second half of 2021 and abroad in other Middle Eastern and African locations," said Yves-Stephane Couture, vice-president of sales for Diagnos.

About Diagnos Inc.

Diagnos is a Canadian company dedicated to early detection of health problems based on its FLAIRE AI platform. The use of the FLAIRE platform allows rapidly modifying and developing its applications such as CARA (computer-assisted retina analysis). CARA's AI-based image-enhancement algorithms provide sharper, clearer and easier-to-analyze traditional retinal images that can be analyzed. CARA is a cost-effective tool for real-time screening in a large number of patients. CARA has been approved by a number of regulators, including Canada (Health Canada), the United States (Food and Drug Administration), Mexico (COFEPRIS), Europe (EC) and the Saudi FDA.

We seek Safe Harbor.